Davita Inc vs ProShares Ultra QQQ ETF — how do they compare? Davita Inc trades at $179.17 (market cap $11.38B), while ProShares Ultra QQQ ETF trades at $92.51. The key difference: ProShares Ultra QQQ ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | QLD | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $240.96 | $100.53 |
52-Week Low | $103.87 | $57.16 |
Enterprise Value | $24.10B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
QLD, the ProShares Ultra QQQ ETF, trades at $92.56, up 1.01% today, with a bullish technical signal from moving averages but neutral oscillators. The ETF, offering 2x daily leverage on the Nasdaq-100, has delivered over 10,000% total return since inception, though it carries amplified risk. Recent institutional buying includes 180 Wealth Advisors increasing its position by 29.4% in Q2 2026, signaling confidence in tech exposure.
The outlook for QLD hinges on tech sector performance, with AI optimism and easing geopolitical tensions as tailwinds. However, leveraged ETF structure risks decay in volatile markets, and a 63.80% historical drawdown underscores volatility. Investors seeking aggressive tech growth may find opportunity, but must tolerate significant swings; diversification and risk management are critical.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →